UTRAP
LIVE

Serial Number

98166206

Owner

utR Biotech

Attorney

Adriano Pacifici

Filing Date

Sep 6, 2023

Add to watchlist:

No watchlists yet
View on USPTO

UTRAP Trademark

Serial Number: 98166206

UTRAP is a trademark filed by utR Biotech on September 6, 2023. The trademark is classified under Class 1 (Chemicals), Class 5 (Pharmaceuticals). The application is currently pending registration.

Owner Contact Info

utR Biotech (4 trademarks)

19 Point West Drive
Winnipeg, MB R3T5J4 , CA

Entity Type: 03

Trademark Details

Filing Date

September 6, 2023

Registration Date

Not Registered

Published for Opposition

June 25, 2024

Goods & Services

Lipid nanoparticles for use in the manufacture of pharmaceuticals, namely, for use in the manufacture of pharmaceutical preparations containing surface chemistry for attachment of any protein, peptide and molecule to bind proteins of interest for preventing and treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, and metabolic disorders; Biochemical preparations for scientific medical research for use in the manufacture of pharmaceuticals for preventing and treating viruses, respiratory disorders, rare diseases, cancers, neurological disorders, cardiovascular disorders, inflammatory disorders, immunoregulatory disorders, metabolic disorders; Reagents for scientific research and medical research use; Chemical reagents for non-medical purposes; Diagnostic reagents for clinical or medical laboratory use; chemistry reagents for scientific research and medical research use; Reagents comprised of nanoparticles for scientific research and medical research use; Reagents comprised of capsids for scientific research and medical research use; Reagents, namely, lipid nanoparticles, for scientific research and medical research use

Pharmaceutical products, namely, lipid nanoparticles, for treating respiratory diseases; Pharmaceutical preparations for treating respiratory diseases, namely, a lipid-enabled drug for binding to agents of interest in particular viruses, bacteria, free-circulating proteins in the body; Pharmaceutical agents for treating respiratory diseases in the nature of biological blocking agents in the form of lipid nanoparticles that facilitate the binding of viruses, bacteria, protein of interest in biological fluids; Pharmaceutical preparations for the treatment of diseases and disorders, namely, allergies, autoimmune diseases, cancer, cardiovascular diseases, genetic diseases, hematological diseases, infectious diseases, inflammatory diseases, metabolic diseases, neurological diseases, ocular diseases and respiratory diseases

Filing History

NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 20, 2026 EXRA
SOU EXTENSION 3 GRANTED
Feb 20, 2026 EX3G
SOU EXTENSION 3 FILED
Feb 20, 2026 EXT3
SOU TEAS EXTENSION RECEIVED
Feb 20, 2026 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Aug 21, 2025 EXRA
SOU EXTENSION 2 GRANTED
Aug 20, 2025 EX2G
SOU EXTENSION 2 FILED
Aug 20, 2025 EXT2
SOU TEAS EXTENSION RECEIVED
Aug 20, 2025 EEXT
NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Feb 20, 2025 EXRA
SOU EXTENSION 1 GRANTED
Feb 19, 2025 EX1G
SOU EXTENSION 1 FILED
Feb 19, 2025 EXT1
SOU TEAS EXTENSION RECEIVED
Feb 19, 2025 EEXT
NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Aug 20, 2024 NOAM
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jun 25, 2024 NPUB
PUBLISHED FOR OPPOSITION
Jun 25, 2024 PUBO
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Jun 5, 2024 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
May 16, 2024 CNSA
TEAS/EMAIL CORRESPONDENCE ENTERED
May 13, 2024 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
May 13, 2024 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
May 13, 2024 TROA
NOTIFICATION OF NON-FINAL ACTION E-MAILED
May 3, 2024 GNRN
NON-FINAL ACTION E-MAILED
May 3, 2024 GNRT
NON-FINAL ACTION WRITTEN
May 3, 2024 CNRT
ASSIGNED TO EXAMINER
May 1, 2024 DOCK
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Sep 28, 2023 NWOS
NEW APPLICATION ENTERED
Sep 9, 2023 NWAP